FilingSEC EDGAR8-K
Emergent BioSolutions Lowers 2026 Annual Revenue Guidance
· SEC accepted
StageGuidance Revision
Filing content
The company lowered its 2026 annual revenue guidance and outlined business strategies including debt restructuring and cost reduction initiatives.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…